The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.

Glenn J HannaJi Eun BaeJochen H LorchRobert I HaddadVickie Y JoJonathan D SchoenfeldDanielle N MargalitRoy B TishlerLaura A GoguenDonald J AnninoNicole G Chau

Published in: The oncologist (2020)

Results of this study showed an improved disease-free and overall survival in patients treated with adjuvant trastuzumab for high-risk salivary gland cancers with strong HER-2/neu staining intensity. Following recurrence or metastatic spread, sequential HER-2, and androgen-directed therapies may benefit certain patients with salivary gland cancer.

Keyphrases

early stage
epidermal growth factor receptor
free survival
small cell lung cancer
squamous cell carcinoma
papillary thyroid
metastatic breast cancer
childhood cancer
high intensity
squamous cell
flow cytometry